Why can the agreement reduce 3M’s litigation uncertainty?

  • 3M has reached an agreement with plaintiffs in multidistrict litigation involving aqueous film-forming foam (AFFF). Bernstein previously viewed this litigation as the largest source of uncertainty among several categories of PFAS-related lawsuits.
  • The firm says the agreement covers 99% of personal injury claims with clear, predictable cash flows. It therefore views the agreement as a positive development that also points to a possible resolution of the company’s broader PFAS liabilities.

Why is the firm still unconcerned about cash pressure despite higher-than-expected payments?

  • Bernstein estimates the present value of PFAS-related payments at approximately 5.8 billion dollars, substantially above its previous forecast of 1 billion to 1.5 billion dollars. However, significant payments are not expected to begin until 2028 and will continue through 2034.
  • The firm believes payments over time reduce survival and default risks; 3M also announced a 6 billion-dollar share buyback and a quarterly dividend, signaling relatively ample liquidity to the market.
  • In its discounted cash flow valuation supporting a 197-dollar price target, Bernstein separately assumes a present value of 6 billion dollars for PFAS-related cash outflows net of insurance recoveries, and assigns 3M a Market Perform rating.

What liabilities could still affect the final bill?

  • Bernstein understands that plaintiffs may still sue after symptoms emerge, so the agreement primarily addresses current claims. The company says remaining and future personal injury claims will be managed through multiple settlement mechanisms.
  • These mechanisms include payments conditional on plaintiffs joining the resolution and a 680 million-dollar reserve fund included in the financial commitments; the company also expects the court to set evidentiary and time-limit requirements for future lawsuits.
  • Beyond the multidistrict litigation, 3M also faces natural resource damage claims, state attorneys general litigation, international lawsuits, and disputes with insurers over coverage.